Global Citizenship

Letter from Greg Lucier

Every day, hundreds of thousands of scientists across the globe use Life Technologies products and services to advance science in fields as diverse as personalized medicine, 21st century forensics, and biofuels.

With our workforce of more than 9,000 people in over 100 countries, we use the power of innovation to improve the human condition one discovery at a time. While we are proud of the responsibility we shoulder in moving science forward, we know that to be a truly great company, we also must be a responsible global citizen. We must be dedicated to unyielding ethics, sustainable business practices, and giving back to our communities. I would like to highlight a few of our recent accomplishments:

  • Since 2004, we have reduced our energy consumption by 32 percent and CO2 emissions by 36 percent per unit of sale.
  • We have enhanced our "design-for-environment" program, which re-engineers our product development processes, reducing packaging waste, energy usage, toxic materials, and our carbon footprint at every phase of development, from product ideation to end-of-life disposal.
  • 100 percent of our employees have taken ethics training and are well versed in our Protocol, the company's guide to ensuring that our business is conducted in accordance with legal and ethical guidelines.
  • We established the Life Technologies Foundation, providing grants that aim to demystify and celebrate the world of life science. We also donate millions of dollars in products and provide funding for global disaster relief.
  • Each year, all employees are given paid leave to participate in local volunteer projects. In May 2009, nearly 3,200 employees contributed more than 13,000 hours of volunteer time in over 100 projects worldwide.

Our citizenship efforts helped Invitrogen (prior to the merger with Applied Biosystems) be named to the Dow Jones Sustainability Index. After the merger, Life Technologies also was named to the FTSE4Good Index Series.

In short, we value a culture that is deeply dedicated to the future of science, respects our environment, and is committed to doing the right thing. Global citizenship is not a destination, but a journey, one that Life Technologies will undertake for years to come.

Greg Lucier Signature Greg Lucier Signature Greg Lucier Signature

Recognition for our commitment to Global Citizenship

The former Invitrogen Corporation was selected as a new member of the Dow Jones Sustainability World Index (DJSI World) and named leader of the biotechnology sector for 2008. The company ranked in the top 10% of the world's 2,500 largest companies in terms of sustainability for performance in corporate governance, labor practices, talent development, community involvement, workplace safety, climate change, and environmental management.

Life Technologies was named to the FTSE4Good Index Series, an equity index series that facilitates investment in companies that meet globally recognized citizenship standards, in March 2009.

News

  • TGen Study

    LifeTechnologies Corporation announced that it is collaborating with the Translational Genomics Research Institute (TGen) and US Oncology to sequence the genomes of 14 patients afflicted with triple negative breast cancer whose tumors have progressed despite multiple other therapies. The goal of this first-of-its-kind research collaboration is to demonstrate whether genomic sequencing of cancer tissue can provide clues for treatment strategies for these individuals.

    Read All Close
  • SMS Technology

    Life Technologies Corporation announced early stage results from its single molecule sequencing (SMS) technology. The technology promises to combine virtually unlimited continuous long read lengths with unmatched accuracy to deliver targeted genomic sequence data in a matter of hours, paving the way for sequencing to become a commonplace tool in research laboratories and clinical settings worldwide.

    Read All Close
  • SOLiD PI ANNOUNCED

    Life Technologies Corporation today announced plans for the Applied Biosystems SOLiD(TM) PI System, a new highly accurate, flexible and easy-to-use genomic analysis platform that will bring next-generation sequencing within the grasp of all life science research laboratories worldwide. Early customer adoption of the SOLiD PI System is expected to begin in the second half of 2010.

    Read All Close

Life (Common Stock)